- Conditions
- C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema, Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, Hereditary Angioedema Attack, Hereditary Angioedema Type I, Hereditary Angioedema Type I and II, Hereditary Angioedema Type II, Hereditary Angioedema Type III, Hereditary Angioedema Types I and II, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Interventions
- deucrictibant
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 16, 2026, 12:44 PM EDT